The latest business news around the world. Written by Market Business News's very own editorial team to deliver reliable, up to date, and honest news.

Shire PLC – Company Information

0

Shire PLC – Company Overview

Shire plc
Company Shire PLC
Corporate Headquarters 5 Riverwalk, Citywest Business Campus, Dublin, Ireland
CEO Flemming Ornskov
CFO Jeff Poulton
Industry Pharmaceuticals
Type Public
Founders Dr James Murray, Dennis Stephens, Peter Moriarty, and Geoff Hall
Founded 1986
Stock symbol NASDAQ:SHPG, LSE:SHP
Revenues $6,416.7 million USD (2015)
Operating expenses $4,997.2 million USD (2015)
Net income $1,303.4 million USD (2015)
Employees 5,548 (2015)
Website https://www.shire.com/
Corporate contact number +353 1 429 7700
IR contact number +1 781 482 0945
IR email address [email protected]

Shire PLC is a specialty biopharmaceutical company, headquartered in Dublin, Ireland. The company’s vision is “to transform the lives of people around the world whose health is impacted by rare and other specialized conditions, through providing innovative treatments.”

It focuses on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine.

It has a broad portfolio of pharmaceuticals, including Adderall XR, Vyvanse, Intuniv, Fosrenol, Replagal, Pentasa, VPRIV, Elaprase, Firazyr, Lialda, and Dermagraft.

Shire plc was founded in 1986 by Harry Stratford, Dr James Murray, Dennis Stephens, Peter Moriarty, and Geoff Hall. Its initial products were calcium supplements to help prevent and treat osteoporosis.

It has approximately  5,000 employees in more than 29 countries, with a major operation base in Basingstoke, Hampshire, England, in addition to major offices in Wayne, Pennsylvania and Cambridge, Massachusetts.

The company is publicly listed on the London Stock Exchange (LSE: SHP), and has a secondary listing on the NASDAQ Stock Market (NYSE: SHPG).


Shire PLC – Financial Results

Key figures (in millions of USD) 2015* 2014*
Revenues $6,416.7 $6,022.1
Operating expenses $4,997.2 $4,324.1
Net income $1,303.4 $3,405.5
Total assets $16,609.8 $13,632.1
Cash and cash equivalents at beginning of period $2,982.4 $2,239.4
Cash and cash equivalents at end of period $135.5 $2,982.4

*For the years ended December 31, 2015 and 2014

Source: “Shire PLC. – 2015 Annual Report”


News about Shire PLC reported by our Market Business News team

January 11, 2015: Shire to buy NPS Pharma for $5.2 billion at $46 per share